Age Related Macular Degeneration Clinical Trial
Official title:
Visual Function Tests in Non-Exudative Age-Related Macular Degeneration and Normal Subjects
Verified date | April 2024 |
Source | ORA, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The goal of this study is to assess a battery of visual function tests in subjects with non-exudative age-related macular degeneration
Status | Terminated |
Enrollment | 200 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years to 99 Years |
Eligibility | Inclusion Criteria: - All Subjects Must: 1. Be 60 years of age or older; 2. Provide written informed consent; 3. Be willing and able to follow all instructions and attend the study visits; 4. Must be able to perform all study procedures; Normal Subjects: 5. Have BCVA of 20/25 or better in the study eye; 6. Have no history or clinical evidence of AMD, retinal diseases or any other ocular pathologies in either eye; AMD Subjects: 7. Have BCVA of 20/40 or better in the study eye; 8. Have a clinical diagnosis of non-exudative AMD in the study eye; Exclusion Criteria: All subjects must not have any of the below criteria 1. Have a diagnosis of wet AMD in the study eye; 2. Have any other hereditary or acquired retinal diseases in either eye ; 3. Have glaucoma or other optic nerve diseases in either eye; 4. Have corneal or other anterior segment diseases in either eye; 5. Have significant cataract in the study eye; 6. Have a history of ocular trauma or ocular surgery (other than cataract removal) in the study eye; 7. Have a history of uncontrolled systemic disease (e.g. poorly controlled hypertension or poorly controlled diabetes); 8. Have a history of seizures; 9. On psychotropic medications; 10. Any other symptoms or conditions that could, in the opinion of the investigator, interfere with study procedures. |
Country | Name | City | State |
---|---|---|---|
United States | Andover Eye Associates | Andover | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
ORA, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Critical flicker fusion | Critical flicker fusion will be tested using a computer based test for different stimulus colors, white, red, green and blue. A wide range of luminance and contrast levels will be tested. The subject would be seated in front of the monitor. The non-study eye will be occluded. Subjects would be given adequate practice tests prior to performing the actual test. The stimulus will be presented on the monitor screen and the subject indicates perceiving the stimulus by pressing a test button. | At study visit through study completion, an average of 2 years | |
Secondary | Dark adaptation | Dark adaptation function will be assessed with dilated pupils using computer based stimuli following photo bleach. Subject will be seated in front of the test monitor with best correction in place for the study eye. The subject will be instructed to keep fixating on a red fixation cross in the center of the monitor and respond to perceiving the stimulus presented by pressing the response trigger button. All stimuli will be presented in random order for all intensities presented. The stimulus intensity is programmed to decrease in intensity with time. The test will be terminated after 20 minutes of recording. Dark adaptation curve will be generated and rod-cone recovery time (in minutes) will be derived from the curve. | At study visit through study completion, an average of 2 years | |
Secondary | Reading Tests | Reading tests will be performed using an electronic tablet device. The subject will be seated in a comfortable position with the non-tested eye occluded. The tablet will be set up in a table right in front of the subject at a viewing distance of 40cm. The subject will be given detailed instructions on the test procedures and outcomes. The goal of this test to assess reading speed of the study eye under a variety of conditions such as high contrast-high luminance, low contrast, low luminance, crowded letters, pepper words of different lengths and vanishing optotypes. Each challenge will be tested using a different passage of similar difficulty level. For each passage, reading speed will be estimated as the time taken to accurately read the entire passage and recorded in words per minute (WPM). | At study visit through study completion, an average of 2 years | |
Secondary | Color vision function | Color vision function will be assessed to test L, M and S cone functions. During the test, a letter will briefly flash on the screen. The subject then must verbally identify the letter and/or its orientation. The response of the subject is then recorded by the technician. If correct, the next letter is presented at decreased color contrast relative to the background. The test continues in this manner until the subject incorrectly identifies the presented letter. At that point, the stimulus is presented at the next higher contrast level. This continues until the subject correctly identifies the presented letter. The test then terminates. | At study visit through study completion, an average of 2 years | |
Secondary | Shape discrimination | Shape discrimination will be tested by presenting a two-alternative forced choice stimulus to the subject on a computer device (monitor or tablet). The subject will be asked to identify the stimulus which is modulated and which is not. The test shall be performed at full room lighting for photopic sensitivity as well as in reduced lighting (mesopic) conditions. The effect of eccentricity may be tested by presenting successively larger targets with foveal fixation. | At study visit through study completion, an average of 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03963817 -
Snapshot Camera for AMD
|
||
Recruiting |
NCT04929756 -
Eye Movement Rehabilitation in Low Vision Patients
|
||
Completed |
NCT04779398 -
Association of MPOD Values With Blue Light.
|
||
Recruiting |
NCT03609307 -
Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
|
Phase 2/Phase 3 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Active, not recruiting |
NCT01943396 -
Treatment of AMD With Rheohemapheresis /RHF/
|
Phase 4 | |
Completed |
NCT00963339 -
Age-Related Macular Degeneration (AMD) - Usability Study
|
N/A | |
Completed |
NCT00376701 -
Combination Therapy for Age-Related Macular Degeneration.
|
Phase 2 | |
Terminated |
NCT00347165 -
Intravitreal Bevacizumab for Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00800995 -
Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
|
Phase 3 | |
Completed |
NCT04689789 -
OCTA and Retinal Angiomatous Proliferation
|
||
Completed |
NCT02567604 -
Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
|
||
Completed |
NCT02173496 -
Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
|
||
Recruiting |
NCT01991730 -
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients
|
N/A | |
Active, not recruiting |
NCT01657669 -
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
|
Phase 4 | |
Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
Completed |
NCT00791570 -
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
|
Phase 1 | |
Completed |
NCT00413829 -
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
|
Phase 2 | |
Completed |
NCT00358345 -
PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization
|
Phase 4 |